Barclays downgraded Roche to Equal Weight from Overweight with a price target of CHF 270, down from CHF 350. Roche remains in a "transitional" period, and believe investors want to see more out of the pipeline before sentiment will improve, the analyst tells investors in a research note. "In this market, defense wins championships," writes the firm.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RHHBY:
- Roche to collaborate with Lilly on early diagnosis of Alzheimer’s disease
- Roche announces collaboration with Lilly to enhance early diagnosis of Alzheimer’s disease
- Genentech announces long-term data for Evrysdi in SUNFISH study
- New four year data for Roche’s Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy (SMA)
- Recursion Pharmaceuticals initiated with a Buy at Needham